Editorial: Cardiomyopathies: Current Treatment and Future Options
Internal Medicine-Cardiology, Ubbo Emmius Hospital Norden, Cardiology, Osterstr. 110, 26506 Norden, Germany
J. Clin. Med. 2020, 9(11), 3531; https://doi.org/10.3390/jcm9113531
Submission received: 28 October 2020
/
Accepted: 29 October 2020
/
Published: 31 October 2020
(This article belongs to the Special Issue Cardiomyopathies: Current Treatment and Future Options)
Abstract
:Cardiomyopathies are an essential component in clinical cardiology. The number of different cardiomyopathies have increased a lot due to genetics and newer insights in pathomechanism. The current treatment and future options are demonstrated in advance.
Cardiomyopathies are an essential factor in cardiology with important progress in genetics, medical treatment and treatment with devices. Ablation in order to treat various forms of arrhythmias plays a more and more increased role.
In 1995, the most important cardiomyopathies were dilated cardiomyopathy, hypertrophic cardiomyopathy, restrictive cardiomyopathy and arrhythmogenic right ventricular cardiomyopathy [1].
A lot of other cardiomyopathies have been described in recent years, such as non-compaction cardiomyopathy, takotsubo cardiomyopathy, and many other subtypes of already known cardiomyopathies [2].
In hypertrophic cardiomyopathy, we must differentiate between various forms of hypertrophy. We can offer articles to various types of hypertrophy due to different causes like Amyloid cardiomyopathy and Fabry cardiomyopathy. The same genes for hypertrophic cardiomyopathy can cause non-compaction left ventricle, which is included in our reviews.
The definition of arrhythmogenic cardiomyopathies has changed in recent years; meanwhile, arrhythmogenic dilated cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, and arrhythmogenic left ventricular cardiomyopathy are included. What is more important is the fact that different genes play a crucial role, like Filamin C, Lamin A/C, phospholamban and RBM20. We could invite international experts in this field to write important papers.
The importance of ajmaline testing in arrhythmogenic right ventricular cardiomyopathy and hypertrophic cardiomyopathy is worth a particular paper in order to predict the risk of life-threatening ventricular arrhythmias.
Idiopathic dilated cardiomyopathy has gained intensive interest due to different stages of the disease. Arrhythmogenic dilated cardiomyopathy, non-dilated hypokinetic left ventricle, and dilatation without contraction impairment were described in 2016 [3]. The progress in definition are described by experts in the field.
Several cases of rare cardiomyopathies hide under the term of non-ischemic heart failure with preserved left ventricular ejection fraction and benefit from newer treatment options like tafamidis, and in the near future, mavacamten.
A lot has changed in the definition of cardiomyopathies since 1995, summarized in present papers with increased knowledge in genetics, pathophysiology, medical treatment, the use of devices, and ablation techniques, and future options in treatment are developing in the coming years.
Funding
This research received no external funding.
Conflicts of Interest
The authors declare no conflict of interest.
References
- Richardson, P.; McKenna, W.; Bristow, M.; Maisch, B.; Mautner, B.; O’Connell, J.; Olsen, E.; Thiene, G.; Goodwin, J.; Gyarfas, I.; et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the definition and classification of cardiomyopathies. Circulation 1996, 9, 841–842. [Google Scholar]
- Maron, B.J.; Towbin, J.A.; Zhiene, G.; Antzelewitch, C.; Corrado, D.; Arnett, D.; Moss, A.J.; Seidman, C.E.; Young, J.B. Contemporary definitions and classification of cardiomyopathies. Circulation 2006, 113, 1807–1816. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pinto, Y.M.; Elliott, P.M.; Arbustini, E.; Adler, Y.; Anastasakis, A.; Böhm, M.; Duboc, D.; Gimeno, J.; de Groote, P.; Imazio, M.; et al. Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practise: A position statement of the ESC working group on myocardial and pericardial diseases. Eur. Heart J. 2016, 37, 1850–1858. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2020 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
MDPI and ACS Style
Peters, S. Editorial: Cardiomyopathies: Current Treatment and Future Options. J. Clin. Med. 2020, 9, 3531. https://doi.org/10.3390/jcm9113531
AMA Style
Peters S. Editorial: Cardiomyopathies: Current Treatment and Future Options. Journal of Clinical Medicine. 2020; 9(11):3531. https://doi.org/10.3390/jcm9113531
Chicago/Turabian StylePeters, Stefan. 2020. "Editorial: Cardiomyopathies: Current Treatment and Future Options" Journal of Clinical Medicine 9, no. 11: 3531. https://doi.org/10.3390/jcm9113531
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.
